Fenbendazole and Ivermectin for Prostate Cancer: A Case Series of 130 Patients (July 2026 Update)

Abstract Background: Advanced prostate cancer, including metastatic hormone-sensitive and castration-resistant forms, often develops resistance to standard androgen deprivation therapies, highlighting the need for novel adjunctive strategies. Repurposed antiparasitic agents such as fenbendazole and ivermectin have garnered attention for their potential anticancer properties, supported by…